Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
A Real-World, International, MultICentre, Non-Interventional, Prospective CoHORt to Assess the Clinical and Patient-Reported Outcomes in Adults with MOderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated with Breztri/Trixeo (Budesonide /Glycopyrronium / Formoterol) in Routine Care Settings	PI initiated	Ongoing	Budesonide/ Glucopyrronim/ Formoteral	4	D5980R0012	Abha Private Hospital,King Fahad Medical City (Riyadh)
A Phase 3b, Multicenter, Randomized, Open-Label Study of Risankizumab Compared to Vedolizumab for the Treatment of Adult Subjects With Moderate to Severe Ulcerative Colitis Who are Naïve to Targeted Therapies	AbbVie	Ongoing	Risankizumab	3b	M25-540	King Khalid University Hospital (Riyadh), King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City, National Guard Health Affairs (Riyadh)
A Multicenter, Single Arm, Open Label Biopsy Study to Evaluate Structural and Functional Changes in Kidneys of Adult Patients with Iga Nephropathy Receiving Iptacopan on Top of Supportive Care	Novartis/ ArabMed	Ongoing	Iptacopan (LNP023)	2a	CLNP023A2201	King Faisal Specialist Hospital and Research Center (Riyadh).
DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer (DESTINY BTC01 - D781PC00001)	AstraZeneca	Ongoing	Trastuzumab-Deruxtecan,Rilvegostomig &Durvalumab	3	D781PC00001	King Faisal Specialist Hospital and Research Center (Riyadh).
A Retrospective Phase IV Study: Use of the clinical decision support tool (CDST) in predicting probability of response to vedolizumab in Middle Eastern Crohn’s Disease patients: the ME-VOICE study (Middle East Vedolizumab Outcomes probability In CDST Evaluation	Saudi Gastroenterology Association (SGA)	Ongoing	Vedolizumab	4	CCR-2024-2	King Khalid University Hospital (Riyadh)
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel- group study with an open-label period and long-term extension to assess the efficacy and safety of rilzabrutinib in participants with warm autoimmune hemolytic anemia (wAIHA)	Sanofi Arabia Trading Company Limited / ArabMed	Ongoing	Rilzabrutinib	3	EFC17360	King Faisal Specialist Hospital and Research Center (Riyadh).
A Global Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of mRNA-3705 in Participants with Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency	Moderna/ Balsam CR	Ongoing	MRNA 3705	2	mRNA-3705-P101	King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh) , King Abdullah Specialist Children's Hospital (Riyadh)
Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction	Viatris Innovation GmbH / IQVIA	Ongoing	(ACT-246475) is a 2-phenyl-pyrimidine derivative selatogrel	3	ID-076A301 / SOS-AMI	King Faisal Specialist Hospital and Research Center (Riyadh),King Saud University Medical City (Riyadh), King Fahad Specialist Hospital (Dammam)
A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator’s Choice in Participants with Relapsed/Refractory Follicular Lymphoma	Celgene Corporation / Balsam Clinical Research	Ongoing	Golcadomide / Rituximab	3	CA0731003	King Faisal Specialist Hospital and Research Center (Riyadh)
Randomized, Multicenter, Multinational, Double-Blind Study to Compare the Pharmacokinetics, Efficacy, Safety and Immunogenicity of MB12 (Proposed PembrolizumabBiosimilar) versus Keytruda® in Combination with Chemotherapy for the Treatment of Patients with Advanced Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (BENITO Study)	mAbxience Research SLU / Balsam	Ongoing	MB12 (proposed pembrolizumab biosimilar)	3	MB12-C-02-24	King Saud University Medical City (Riyadh)